SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing a sharp sell-off driven by a confluence of negative sentiment, including a federal jury finding that Elon Musk defrauded Twitter shareholders and concerns regarding broader macroeconomic instability. The community is deeply divided, with bears pointing to falling delivery numbers and operational scrutiny as evidence of a structural decline, while loyal bulls continue to highlight upcoming projects like TeraFab and the potential for a rebound as reasons to maintain their positions.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy is trending as investors debate the long-term potential of the project, with many in the community expressing unwavering patience for a future breakout despite current price volatility. Supporters are actively highlighting the project's utility and health-focused mechanics, often drawing comparisons to historical market recoveries to justify their continued accumulation.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is experiencing significant volatility as investors debate the impact of the Kodiak Building Partners acquisition alongside ongoing concerns regarding share dilution and macro headwinds in the construction sector. While some community members remain bullish on Brad Jacobs' long-term consolidation strategy and anticipated acquisition pipeline, others are expressing frustration over the recent downward price pressure and uncertainty surrounding the integration timeline.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as investors focus on its integration into the AI-native economy, with community discussion highlighting its role in chain abstraction, privacy-focused protocols, and recent infrastructure developments. Many are closely watching the balance between retail accumulation and institutional activity while expressing optimism about its long-term utility in the decentralized AI landscape.

KKR & Co., Inc. operates as an investment firm. It offers alternative asset management as well as capital markets and insurance solutions. The firm's business segments include Asset Management and Insurance Business. The Asset Management segment engages in providing private equity, real assets, credit and liquid strategies, capital markets, and principal activities. The Insurance Business segment offers retirement, life insurance and reinsurance solutions to clients across individual and institutional markets. The company was founded by Henry Kravis, George R. Roberts, and Jerome Kholberg on May 1, 1976 and is headquartered in New York, NY.

KKR & Co. Inc

KKR & Co. Inc.

KKR is actively being discussed as a major player in the private credit and infrastructure space, with investors noting a positive trend following record fee-related earnings and significant capital raising milestones. The community remains focused on KKR's ongoing pivot toward permanent capital and wealth management, viewing the stock as a compelling long-term play despite broader market volatility and questions surrounding the liquidity of private markets.

LayerX is a web3 infrastructure and innovation ecosystem focused on helping builders go from idea to real, sustainable products. The platform connects hackathons, developer tools, incubation programs, and community-driven ecosystems under a single framework. LayerX supports both technical and non-technical participants by providing access to mentorship, partnerships, hackathons, onchain tasks, and more.  Its products enable teams to prototype, validate, and scale projects while aligning incentives between builders, communities, and partners. The LX token acts as the shared economic layer across the ecosystem, supporting participation, staking, governance, and access to ecosystem features.

LayerX

LayerX, formerly known as Bepro, is drawing significant community interest as investors discuss its low market capitalization, potential for long-term growth, and recent developments within its ecosystem. Supporters are actively sharing bullish perspectives on the project's utility and future potential while tracking technical indicators and looking for signs of broader adoption.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors capitalize on its recent NYSE listing, which provides rare public market access to high-profile private AI and tech companies like Anthropic, OpenAI, and SpaceX. While the community is actively debating the significant premium over the fund's net asset value and the impact of a six-month lockup on available float, many are focused on the stock's high volatility and potential for momentum-driven price swings.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstone shares are under pressure as investors react to mixed signals regarding private credit exposure and shifting regulatory landscapes, despite the firm reporting a significant earnings beat and record assets under management. Market participants are actively debating whether the recent dip represents a buying opportunity in a high-growth financial leader or a warning sign of broader systemic risks within the alternative asset sector.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is currently capturing significant market interest as it benefits from surging demand for AI-driven chip fabrication equipment, with community members actively monitoring its strong relative strength against industry peers. Investors are closely tracking upcoming earnings while debating the stock's valuation and potential upside against the backdrop of broader semiconductor sector consolidation.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as community discussions center on the Supreme Court's potential involvement in its patent infringement case against Hikma, following the Solicitor General's filing. Investors are also closely monitoring the upcoming EMT2 trial results and potential M&A activity as the company continues its restructuring and cost-cutting initiatives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Glenmark launched semaglutide under the brand name GLIPIQ for adults with Type 2 diabetes at ₹325 ($3.5) per week on Saturday.</li><li>The launch comes in a market where GLP-1 drugs such as Ozempic and Mounjaro are available at a much steeper cost.</li><li>The lower price point will reduce the cost barrier for diabetes and weight-loss treatment in India.</li></ul>As demand for diabetes and weight-loss treatments rises, Glenmark Pharmaceuticals Ltd (GLENMARK.NSE) has introduced a cost-effective version of semaglutide in India, aiming to improve affordability in a market dominated by higher-priced alternatives.Glenmark&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://glenmarkpharma.com/gpl_pdfs/media/PR_Glenmark%20Pharmaceuticals%20launches%20GLIPIQ%E2%93%87.pdf">launched</a> semaglutide under the brand name GLIPIQ for adults with Type 2 diabetes on Saturday, with weekly treatment costs starting at ₹325 ($3.5). The drug belongs to a class of medicines that help control blood sugar levels and are also used for weight management.The launch came in the market as GLP-1 drugs like Ozempic and Mounjaro are available at significantly higher prices. Weekly treatment using these can cost around ₹3,000 ($21) or more, depending on dosage and brand. At a more granular level, a 1 mg dose of Ozempic is priced near ₹12,000 ($128), while a 2.5 mg Mounjaro injection costs about ₹3,300 ($35).In comparison, GLIPIQ is priced between ₹325 and ₹440 ($3.5 to $4.7) per week, depending on dosage.Commenting on the launch, Alok Malik, President and Business Head, India Formulations at Glenmark Pharmaceuticals, said, “Affordability is one of the biggest barriers to initiating advanced diabetes treatment in India. With GLIPIQ, we are setting a new benchmark in affordability for GLP-1 drugs, with weekly treatment starting at ₹325.”<a href="https://stocktwits.com/symbol/GLENMARK.NSE/sentiment">GLENMARK.NSE</a> closed at ₹2,180 ($23.19) on Friday, trading up by almost 4%. On Stocktwits, the retail sentiment around GLENMARK.NSE improved from ‘neutral’ to ‘bullish,’ as chatter levels around it remained ‘normal’ over the past day.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_21_at_2_24_01_PM_png_9e2a9418ca.webp" alt="Screenshot 2026-03-21 at 2.24.01 PM.png" width="1160" height="684"><figcaption>StocktwitsGLENMARK.NSE retail sentiment on March 21 as of 2:42 a.m. ET | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Global GLP-1 Market</h2>The GLP-1 drug market has been dominated by Novo Nordisk (NVO) and Eli Lilly (LLY), whose products Ozempic and Monjaro are widely used for diabetes and weight management. However, patent expiries have reshaped the landscape.&nbsp;According to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-03-20/ozempic-copies-to-cost-14-in-india-as-generic-glp-1-era-starts">report</a>, Canada was among the first to lose patent protection for semaglutide earlier this year. The patent for semaglutide is also set to expire this month in China, Brazil, and Turkey. This positioned India as one of the first major markets to see the entry of lower-cost alternatives, as domestic drugmakers began launching competing products at a much lower cost.&nbsp;<h2 class="st-heading-2">How Is Stocktwits Reacting?</h2><stembedurl>https://www.stocktwits.com/TrendonomicsHD/message/648064809</stembedurl>One user on Stocktwits said that Glenmark is showing strong bullish technical signals despite a bearish sentiment. They pointed out that the stock appears to be in a "Stage 2 breakout," meaning it is starting to edge higher.Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-whale-who-called-crash-warns--debt-hits-wwii/cZ3i55RRIiW">Whale Who Shorted Bitcoin In Black Swan Event Warns As US Debt Hits Highest Since World War II</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. While some doctors are prescribing it "off label" for weight loss, on March 17, 2026 in Sydney, Australia. (Photo by Steve Christo/Getty Images)

Glenmark Debuts Budget Semaglutide In India, Undercutting Ozempic By Over 80%

As the patents for semaglutide near expiry in several countries this month, India has introduced a cost-effective alternative.

Equity

As the patents for semaglutide near expiry in several countries this month, India has introduced a cost-effective alternative.


Rs 325–4,200/month: Dr Reddy’s, Sun Pharma, Glenmark kick off generic semaglutide price war

… Reddy’s Laboratories, Sun Pharma , Glenmark Pharmaceuticals , Alkem Laboratories, Zydus Lifesciences … , and Natco Pharma . Eris Lifesciences, which has a … first Indian pharma company to receive approval from the Drugs Controller General …

Sun Pharma, Dr Reddy's, Glenmark Launch Generic Semaglutide Injection in India

… markets." Another homegrown pharma major, Glenmark Pharmaceuticals Ltd also launched its …

Sun Pharma, Dr. Reddy’s, Zydus, Glenmark roll out generic Semaglutide

The generic drugmakers, with many more expected to make announcements, are eyeing a share of the market for Semaglutide in India, which is estimated to be $1 billion over the next couple of years

Affordable Diabetes Management: Indian Pharma Giants Launch Generic Semaglutide

Indian pharmaceutical giants, including Sun Pharma, Dr Reddy's, and Glenmark, have announced the release of their generic versions of semaglutide injection, marking a significant step in diabetes and weight management care in India.

Glenmark Launches Low-Cost Semaglutide GLIPIQ in India to Expand Diabetes Care

The latest announcement is out from Glenmark Pharmaceuticals Limited ( ($IN:GLENMARK) ). Glenmark Pharmaceuticals has launched GLIPIQ (semaglutide)...

Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture, and marketing of pharmaceutical products. It operates through the following geographical segments: India, North America, Europe, Latin America, and Rest of the World. The company was founded by Gracias Saldanha on November 18, 1977 and is headquartered in Mumbai, India.

GLENMARK.NSE
Glenmark Pharmaceuticals Ltd.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest GLENMARK.NSE News

GLENMARK.NSEGlenmark Pharmaceuticals Ltd.